188 results on '"Kumar, Shaji K."'
Search Results
2. Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma
3. Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
4. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
5. Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
6. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
7. Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
8. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
9. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
10. Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma
11. Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
12. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience
13. Clinical characteristics and outcomes in biclonal gammopathies
14. Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma.
15. Proposed risk‐scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
16. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation
17. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients
18. Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
19. Prognostic significance of acquired 1q22 gain in multiple myeloma
20. Limiting early mortality: Doʼs and donʼts in the management of patients with newly diagnosed multiple myeloma
21. Outcomes of primary refractory multiple myeloma and the impact of novel therapies
22. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma
23. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T
24. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
25. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
26. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
27. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials
28. Current approaches to management of high‐risk multiple myeloma
29. Trends and outcomes of modern staging of solitary plasmacytoma of bone
30. Myeloma ASH 2010 highlights
31. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
32. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
33. Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
34. Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
35. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio
36. Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
37. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease
38. Role of imaging in multiple myeloma
39. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia
40. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
41. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
42. A phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
43. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
44. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients.
45. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
46. Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update.
47. Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
48. Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells
49. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients
50. Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.